- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01633138
Performance-based Reinforcement to Enhance Cognitive Remediation Therapy
March 4, 2020 updated by: Yale University
Pilot Study of Performance-based Reinforcement to Enhance Cognitive Remediation Therapy for Substance Users
The purpose of this study is to investigate whether monetary reinforcement for performance will enhance the effects of cognitive remediation therapy for substance users seeking treatment at an outpatient facility.
Study Overview
Status
Completed
Conditions
Detailed Description
Forty individuals seeking treatment for an alcohol or cocaine use disorder at the Substance Abuse Treatment Unit (SATU) will be randomized to receive cognitive remediation therapy with or without additional compensation based on performance.
Participants will use the computerized cognitive remediation program (PSSCogRehab 2012) three times per week for four weeks.
The primary outcome measure will be an improved performance on the computerized tasks, with secondary outcomes of changes in cognitive functioning (e.g., attention, concentration, memory) as measured by neuropsychological tests between baseline and post-treatment.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Substance Abuse Treatment Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 to 60 years old
- Primary Alcohol and/or Cocaine Abuse/Dependence Diagnosis
- Abstinence from all drugs/alcohol for 30 days
- Mild cognitive impairment
- Sufficiently stable and plan to commit to 4 weeks of outpatient treatment
- Fluent in English and 6th grade reading ability
Exclusion Criteria:
- Severe cognitive impairment indicative of dementia
- Untreated bipolar or psychotic disorder
- Have current legal case pending such that incarceration during 4-week study is likely
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: CRT-S
Cognitive Remediation Therapy - Standard
|
Computerized cognitive remediation therapy provided three times per week for four weeks
|
|
Experimental: CRT-CM
Cognitive Remediation Therapy plus Contingency Management
|
Standard cognitive remediation therapy plus monetary incentives based on performance provided three times per week for four weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improvement in performance scores on computerized cognitive remediation tasks
Time Frame: 4 weeks
|
Performance scores on various computerized cognitive remediation tasks will be measured repeatedly during the 4 week study.
These scores include "time to completion", "number of errors", "number of words correctly recalled", and "percentage of task completed"
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improved cognitive function on neuropsychological tests
Time Frame: 4 weeks
|
Change in cognitive function between baseline and post-treatment will be measured by performance on neuropsychological tests, such as Trail Making Test A & B, Wisconsin Card Sort Test, Digit Symbol Test from WAIS-IV, and the Continuous Performance Test-II (CPT-II).
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Brian D Kiluk, PhD, Yale School of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2012
Primary Completion (Actual)
December 1, 2014
Study Completion (Actual)
December 1, 2014
Study Registration Dates
First Submitted
June 27, 2012
First Submitted That Met QC Criteria
June 29, 2012
First Posted (Estimate)
July 4, 2012
Study Record Updates
Last Update Posted (Actual)
March 9, 2020
Last Update Submitted That Met QC Criteria
March 4, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1205010253
- P50DA009241 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance-Related Disorders
-
University of Wisconsin, MadisonNational Institute on Drug Abuse (NIDA); Rush University Medical CenterCompletedSubstance-Related Disorders | Substance Use | Substance AbuseUnited States
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Substance Use | Substance Use Disorders | Substance Abuse | Substance Dependence | Substance Related Problem
-
US Department of Veterans AffairsCompletedAlcoholism | Substance Use Disorders | Substance Abuse | Alcohol Abuse | Substance DependenceUnited States
-
VA Office of Research and DevelopmentActive, not recruiting
-
National Institute on Drug Abuse (NIDA)CompletedSubstance-related Disorders
-
Norwegian University of Science and TechnologyCompletedSubstance-related DisordersNorway
-
University Hospital, Basel, SwitzerlandPsychiatric Hospital of the University of BaselCompleted
-
University of LuebeckFederal Ministry of Health, GermanyCompletedSubstance-related Disorders
-
University of Illinois at Urbana-ChampaignCompletedSubstance-related Disorders
-
University of NebraskaCompletedSubstance-related Disorders | Alcohol-related DisordersUnited States
Clinical Trials on Cognitive Remediation Therapy - Standard
-
Yale UniversityCompletedCancer | Cancer of the ProstateUnited States
-
Central Mental HospitalCompletedSchizophrenia | Schizoaffective Disorder | Cognitive DeficitsIreland
-
Assistance Publique Hopitaux De MarseilleCompletedChildren Born Extremely Premature | Disturbance of Visuo-spatial Working MemoryFrance
-
Gemma Garrido GarcíaCompleted
-
Fundació Sant Joan de DéuCompletedIndication for Modification of Patient Cognitive StatusSpain
-
Beykoz UniversityUskudar University; Istanbul Nisantasi UniversityRecruitingCognitive Dysfunction | Schizophrenia Disorders | Emotion Regulation DisordersTurkey
-
South London and Maudsley NHS Foundation TrustCompleted
-
Fraser HealthMinistry of Social Development and Poverty Reduction, British ColumbiaCompletedSchizophrenia and Related Disorders | Psychotic DisorderCanada
-
The Royal Ottawa Mental Health CentreNot yet recruiting
-
Centre for Addiction and Mental HealthCompletedSchizophrenia | Cognitive Deficit | Cognitive Remediation | Functional Impairment | Late Life SchizophreniaCanada